Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Clin Cancer Res. 2021 Feb 16;27(9):2481–2493. doi: 10.1158/1078-0432.CCR-20-3944

Figure 5. Pre- and Post-Tavo/nivolumab clinical images and application of CXCR3-GS in melanoma.

Figure 5

A. Baseline breast nodule (treated), scalp metastases (untreated) and lung metastases (Untreated). B. After 1 cycle of Tavo and 3 months IV nivolumab therapy. C. CXCR3-GS score in baseline tumor samples from metastatic melanoma patients that went on to be non-responders or responders to subsequent nivolumab therapy. D. Data from (C) divided by previous response/treatment with ipilimumab. All error bars represent mean ± SEM *p<0.05